about
STAT3: A Novel Molecular Mediator of Resistance to ChemoradiotherapyEvaluation of prediction models for the staging of prostate cancer.Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate CancerExpressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: a fractal geometrical model of prostate carcinoma.The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?Gleason inflation 1998-2011: a registry study of 97,168 men.Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
P2860
Q27003190-9BF456EE-B3E1-4C91-B39E-A9FB20082A22Q35044520-16BA94D5-EA06-48A7-82F0-C4293BF4BCF4Q35735074-D67880F2-30E8-40A3-A631-FC7BE41996EBQ37606770-C81A5684-5032-499E-94A9-7CACA0EEF8B5Q38302346-7051954D-A5C9-424C-B5F3-5D3A885ADF25Q38391339-BCD60BF7-96A4-4196-82BC-E529AE2BA3A3Q39199397-BAF006A8-B8CE-4120-A741-958E0597FC3DQ40707324-13F0A2C5-6E43-43D3-9639-BDB8C3C9280AQ42669921-E907DFC7-CD48-486F-BAD4-0C4AAA49B4B6Q47894036-6D160801-878C-4937-93A5-723BA07D1EB6
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Management of low (favourable)-risk prostate cancer
@ast
Management of low (favourable)-risk prostate cancer
@en
Management of low (favourable)-risk prostate cancer
@nl
type
label
Management of low (favourable)-risk prostate cancer
@ast
Management of low (favourable)-risk prostate cancer
@en
Management of low (favourable)-risk prostate cancer
@nl
prefLabel
Management of low (favourable)-risk prostate cancer
@ast
Management of low (favourable)-risk prostate cancer
@en
Management of low (favourable)-risk prostate cancer
@nl
P2860
P1433
P1476
Management of low (favourable)-risk prostate cancer
@en
P2093
H. Ballentine Carter
P2860
P304
P356
10.1111/J.1464-410X.2010.10489.X
P407
P577
2011-12-01T00:00:00Z